A Phase I Open-Labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2).
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 6280; Caffeine; Midazolam
- Indications Anxiety disorders
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 01 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Jan 2009 New trial record.